Mach-1 Financial Group’s Evolent Health EVH Stock Holding History

Mach-1 Financial Group’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22	Closed	–	–	240
2021 Q4	$0	Buy	+22	New	+$631	﹤0.01%	260

Other funds holding EVH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Mach-1 Financial Group's EVH Position: Q1 2022 in Review

Mach-1 Financial Group sold out of Evolent Health (EVH) in Q1 2022, closing a stake of 22 shares.

Mach-1 Financial Group first reported a position in EVH in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 218 funds tracked by Wall St. Rank hold EVH as of Q1 2022.

Mach-1 Financial Group reported no remaining Evolent Health position as of Q1 2022 after selling out during the quarter.
Mach-1 Financial Group sold 22 Evolent Health shares in Q1 2022.
Mach-1 Financial Group first reported a position in Evolent Health in Q4 2021 and held it in 1 quarter.
Mach-1 Financial Group's Evolent Health position peaked at $0 in Q4 2021.
218 funds tracked by Wall St. Rank held Evolent Health as of Q1 2022.

Based on Mach-1 Financial Group's 13F filing for Q1 2022, filed 6 May 2022.